Dai ichi Life Insurance Company Ltd Sells 10,000 Shares of DexCom, Inc. (NASDAQ:DXCM)

Dai ichi Life Insurance Company Ltd lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,305 shares of the medical device company’s stock after selling 10,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in DexCom were worth $959,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Jennison Associates LLC grew its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after purchasing an additional 435,401 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $78.10 on Thursday. The company’s 50 day moving average is $71.11 and its 200-day moving average is $88.51. The firm has a market cap of $30.51 billion, a P/E ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,431 shares of company stock worth $399,319 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Robert W. Baird upped their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Wells Fargo & Company lifted their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.